MYOM2 and Thrombocytopenia: All three patients had rising M-proteins at enrollment (patient 12 also had progressing Bence-Jones paraprotein, while patient 5 had progressing serum free light chains and worsening thrombocytopenia) and met criteria for SD, though further exposure to tivantinib yielded evidence of some benefit only in patient 12.